Medtronic Raises 2027 Forecasts Amid Heart Device Surge

Medtronic has boosted its fiscal 2027 revenue and profit forecasts, buoyed by a surge in demand for heart devices used in complex cardiovascular procedures. The company announced on Tuesday that it now anticipates annual organic revenue growth between 7.25% and 7.75%, an increase from its previous projection of 6.75% to 7.25%.

Strategic Investments and Acquisitions

In a strategic move to enhance its portfolio, Medtronic has committed $80 million to invest in Pi-Cardia, a maker of heart-valve repair devices, with an option to acquire the company for $210 million. Additionally, Medtronic has invested $700 million in Cornerstone Robotics, securing rights to distribute a robotic surgical device in select markets outside the United States. CEO Geoff Martha highlighted the potential of Cornerstone's Sentire device, noting its complementarity to Medtronic's existing Hugo device, particularly in emerging markets where penetration of soft tissue robotic surgery remains below 1%.

Strong Performance Across Segments

Medtronic's cardiovascular segment reported a significant 19.5% increase in quarterly sales, reaching $3.93 billion. This growth was largely driven by an 88% increase in its pulsed field ablation portfolio, which is used to treat irregular heart rhythms. The company also reported an adjusted quarterly per share profit of $1.45 on revenue of $9.76 billion, surpassing analysts' expectations of $1.39 per share on $9.55 billion in sales, according to data compiled by LSEG.

Financial Considerations and Market Outlook

The company's Chief Financial Officer, Thierry Pieton, noted that Medtronic received tariff refunds that nearly offset the duties paid during the quarter, though future refunds have not been factored into their outlook. Despite these uncertainties, Medtronic remains optimistic, with Martha emphasizing the breadth of performance across its business lines and the growing contributions from new growth platforms.

As Medtronic continues to prioritize high-growth segments within the medtech industry, the company's strategic investments and robust demand for its heart devices position it well for sustained growth. The company has adjusted the lower end of its fiscal 2027 adjusted per share profit forecast to $5.94, maintaining the upper end at $6.